Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435606 | 0.80 | MAPK14 (0.56) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL9435546 | 0.78 | MAPK13 (0.56) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL11172466 | 0.78 | MAPK14 (0.57) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL4285506 | 0.77 | MAPK14 (0.69) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5098384 | 0.77 | MAPK14 (0.69) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL9666048 | 0.77 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL5446798 | 0.77 | GCGR (0.56) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL1172425 | 0.76 | KDM4E (0.60) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL31029951 | 0.76 | MAPK13 (0.89) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL67984 | 0.76 | MAPK13 (0.89) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | BEIERSDORF, AG | 2007-08-09 | — | — | US | disclosed |
| US-7223781-B2 | 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040116695-A1 | 2-Mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373217-A1 | 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS | Beiersdorf AG (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076951-A1 | 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS | BEIERSDORF AG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | PTGS2, PTGES2, DHFR | MAPK13 3380/4885MAPK12 3274/4885MAPK11 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.